Identification

Name
Norgestrel
Accession Number
DB09389
Type
Small Molecule
Groups
Approved
Description

Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active.

Structure
Thumb
Synonyms
  • 17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one
  • LD norgestrel
  • Methylnorethindrone
External IDs
WY 3707 / WY-3707 / WY3707
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ovrette TabletsTablet0.075 mgOralPfizerNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CryselleNorgestrel + Ethinyl EstradiolKitTeva2002-07-24Not applicableUs00555 9049 58 nlmimage10 4236a175
CryselleNorgestrel + Ethinyl EstradiolKitA S Medication Solutions2002-07-242017-06-20Us
CryselleNorgestrel + Ethinyl EstradiolKitPhysicians Total Care, Inc.2003-10-16Not applicableUs
ElinestNorgestrel + Ethinyl EstradiolKitNorth Star Rx Llc2012-01-07Not applicableUs
Lo-femenal 21 TabletsNorgestrel (300 mcg) + Ethinyl Estradiol (30 mcg)TabletOralPfizer2001-05-142014-04-04Canada
Lo/Ovral-28Norgestrel + Ethinyl EstradiolKitA S Medication Solutions1976-03-012017-06-20Us
Low-OgestrelNorgestrel + Ethinyl EstradiolKitOralPhysicians Total Care, Inc.2009-09-24Not applicableUs
Low-OgestrelNorgestrel + Ethinyl EstradiolKitMayne Pharma2016-08-03Not applicableUs
Low-OgestrelNorgestrel + Ethinyl EstradiolKitActavis Pharma Company1999-07-282018-03-31Us52544 0847 28 nlmimage10 5245a92d
OgestrelNorgestrel + Ethinyl EstradiolKitActavis Pharma Company1999-12-15Not applicableUs52544 0848 28 nlmimage10 18498c6c
Categories
UNII
3J8Q1747Z2
CAS number
6533-00-2
Weight
Average: 312.453
Monoisotopic: 312.208930142
Chemical Formula
C21H28O2
InChI Key
WWYNJERNGUHSAO-UHFFFAOYSA-N
InChI
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3
IUPAC Name
15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C

Pharmacology

Indication

Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy.

TargetActionsOrganism
AProgesterone receptor
binder
Human
A3-oxo-5-alpha-steroid 4-dehydrogenase 1
inhibitor
Human
UAndrogen receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolNorgestrel may decrease the anticoagulant activities of Acenocoumarol.Approved
AcitretinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Adapalene.Approved
AlitretinoinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Alitretinoin.Approved, Investigational
AmiodaroneThe metabolism of Norgestrel can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Amobarbital.Approved, Illicit
AprepitantThe serum concentration of Norgestrel can be decreased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe serum concentration of Norgestrel can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Norgestrel can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Norgestrel can be decreased when combined with Atomoxetine.Approved
BarbexacloneThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbital.Illicit
BexaroteneThe serum concentration of Norgestrel can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Norgestrel can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Norgestrel can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Norgestrel can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Norgestrel can be increased when it is combined with Ceritinib.Approved
CholestyramineThe serum concentration of Norgestrel can be decreased when it is combined with Cholestyramine.Approved
ClarithromycinThe metabolism of Norgestrel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Norgestrel can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Norgestrel can be decreased when it is combined with Clobazam.Approved, Illicit
ClorindioneNorgestrel may decrease the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Norgestrel can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Norgestrel can be increased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Norgestrel can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Norgestrel can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Norgestrel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Norgestrel can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Norgestrel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Norgestrel can be decreased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Norgestrel can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Norgestrel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Norgestrel can be decreased when combined with Delavirdine.Approved
DicoumarolNorgestrel may decrease the anticoagulant activities of Dicoumarol.Approved
DihydroergotamineThe metabolism of Norgestrel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Norgestrel can be decreased when combined with Diltiazem.Approved
DiphenadioneNorgestrel may decrease the anticoagulant activities of Diphenadione.Experimental
DoxycyclineThe metabolism of Norgestrel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Norgestrel can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Norgestrel can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Norgestrel can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Norgestrel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Norgestrel can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateNorgestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideThe serum concentration of Norgestrel can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Norgestrel can be decreased when it is combined with Felbamate.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Norgestrel.Approved
FluconazoleThe metabolism of Norgestrel can be decreased when combined with Fluconazole.Approved
FluindioneNorgestrel may decrease the anticoagulant activities of Fluindione.Investigational
FluvoxamineThe metabolism of Norgestrel can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Norgestrel resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Norgestrel can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Norgestrel can be increased when it is combined with Fusidic Acid.Approved
GriseofulvinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
HexobarbitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Hexobarbital.Approved
IdelalisibThe serum concentration of Norgestrel can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Norgestrel can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Norgestrel can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Norgestrel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsotretinoinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Isotretinoin.Approved
IsradipineThe metabolism of Norgestrel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Norgestrel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Norgestrel can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Norgestrel can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Norgestrel can be decreased when it is combined with Lamotrigine.Approved, Investigational
LopinavirThe serum concentration of Norgestrel can be decreased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Norgestrel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Norgestrel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Norgestrel can be decreased when it is combined with Lumacaftor.Approved
MethohexitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Methylphenobarbital.Approved
MetreleptinThe serum concentration of Norgestrel can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe serum concentration of Norgestrel can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Norgestrel can be decreased when it is combined with Mitotane.Approved
Mycophenolic acidThe serum concentration of Norgestrel can be decreased when it is combined with Mycophenolic acid.Approved
NefazodoneThe metabolism of Norgestrel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Norgestrel can be decreased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Norgestrel can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Norgestrel can be decreased when it is combined with Nevirapine.Approved
NilotinibThe metabolism of Norgestrel can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Norgestrel can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Norgestrel can be increased when it is combined with Osimertinib.Approved
OxcarbazepineThe serum concentration of Norgestrel can be decreased when it is combined with Oxcarbazepine.Approved
PalbociclibThe serum concentration of Norgestrel can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Norgestrel can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Norgestrel can be decreased when it is combined with Perampanel.Approved
PhenindioneNorgestrel may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Norgestrel can be increased when combined with Phenobarbital.Approved
PhenprocoumonNorgestrel may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Norgestrel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Primidone.Approved, Vet Approved
PrucaloprideThe serum concentration of Norgestrel can be decreased when it is combined with Prucalopride.Approved
RanolazineThe metabolism of Norgestrel can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Norgestrel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Norgestrel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Norgestrel can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Norgestrel can be decreased when combined with Ritonavir.Approved, Investigational
SaquinavirThe serum concentration of Norgestrel can be decreased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Norgestrel.Approved, Investigational, Vet Approved
SildenafilThe metabolism of Norgestrel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Norgestrel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Norgestrel can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Norgestrel can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Norgestrel can be increased when it is combined with Stiripentol.Approved
SugammadexThe serum concentration of Norgestrel can be decreased when it is combined with Sugammadex.Approved
SulfisoxazoleThe metabolism of Norgestrel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Norgestrel can be decreased when it is combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Norgestrel can be decreased when combined with Telithromycin.Approved
ThalidomideNorgestrel may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Thiopental.Approved, Vet Approved
TiclopidineThe metabolism of Norgestrel can be decreased when combined with Ticlopidine.Approved
TioclomarolNorgestrel may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Norgestrel can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Norgestrel can be decreased when it is combined with Tocilizumab.Approved
TopiramateThe serum concentration of Norgestrel can be decreased when it is combined with Topiramate.Approved
Tranexamic AcidNorgestrel may increase the thrombogenic activities of Tranexamic Acid.Approved
TretinoinThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
VenlafaxineThe metabolism of Norgestrel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Norgestrel can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Norgestrel can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinNorgestrel may decrease the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe metabolism of Norgestrel can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D00954
ChemSpider
4383
ChEBI
7630
ChEMBL
CHEMBL2107797
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Norgestrel
ATC Codes
G03FB01 — Norgestrel and estrogenG03AA06 — Norgestrel and ethinylestradiolG03FA10 — Norgestrel and estrogen
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Download (6.67 MB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionEndometrial Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
KitOral
TabletOral
TabletOral0.075 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00583 mg/mLALOGPS
logP3.25ALOGPS
logP3.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)17.91ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity92.03 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-2924000000-eb357f64cb0652555ccb

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Ynones / Tertiary alcohols / Cyclic alcohols and derivatives / Acetylides / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Delta-4-steroid / Cyclohexenone / Ynone / Cyclic alcohol
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
terminal acetylenic compound, 3-oxo steroid, 17-hydroxy steroid (CHEBI:7630)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Hammond GL, Rabe T, Wagner JD: Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol. 2001 Aug;185(2 Suppl):S24-31. [PubMed:11521119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Electron carrier activity
Specific Function
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and andro...
Gene Name
SRD5A1
Uniprot ID
P18405
Uniprot Name
3-oxo-5-alpha-steroid 4-dehydrogenase 1
Molecular Weight
29458.18 Da
References
  1. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S: Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000 Aug;14(4):223-30. [PubMed:11075290]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW: Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 1988 Sep;38(3):325-32. [PubMed:3139361]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Schurenkamper P, Lisse K: [In-vitro studies on the effect of D-norgestrel and norethisterone acetate on the formation of sex steroids in the human ovary]. Endokrinologie. 1978 Feb;71(1):25-34. [PubMed:639763]

Drug created on November 30, 2015 12:10 / Updated on October 02, 2017 06:15